Month: September 2026

SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona.

CHEST 2026 Presentation Details

• Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL Trial
• Session: Top Late-Breaking Abstracts: New Trial Data from Bench to Bronchoscope
• Date/Time: Tuesday, October 20, 2026, 2:09–2:13 p.m. MST
• Presenter: Mark Rubinstein, MD, Chief Medical Officer, Achieve Life Sciences
• Authors: Judith J. Prochaska, PhD, MPH, Stanford University; Neal L. Benowitz, MD, University of California, San Francisco; Dorothy K. Hatsukami, PhD, Masonic Cancer Center, University of Minnesota; Matthew E. Linley-Adams, Achieve Life Sciences; Mark L. Rubinstein, MD, Achieve Life Sciences; Nancy A. Rigotti, MD, Harvard Medical School

The presentation will feature results from ORCA-OL, an open-label study that enrolled 475 adults who previously participated in the ORCA-2, ORCA-3 or ORCA-V1 trials and were actively smoking cigarettes and/or vaping daily. Participants received cytisinicline 3 mg three times daily for 52 weeks with behavioral support. The analysis evaluated abstinence throughout the 52-week treatment period, including biochemically verified four-week sustained abstinence and seven-day point prevalence abstinence.

For more information about the conference, visit https://www.chestnet.org/learning-and-events/events/chest-annual-meeting.

About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Tobacco use is currently the leading cause of preventable death, responsible for more than seven million deaths worldwide and nearly half a million deaths in the United States annually.²,³

In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.¹ In 2025, approximately 1.4 million middle and high school students in the United States reported using e-cigarettes.⁴ There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded Achieve the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine dependence for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products.

About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements regarding the potential benefits of cytisinicline, the potential market for cytisinicline, and the Company’s commercialization plans and readiness. Achieve may not achieve its plans, projections, or other expectations and may not be able to successfully complete its NDA resubmission or obtain regulatory approval for cytisinicline on the anticipated timeline or at all. These statements are based on management’s current expectations and beliefs and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those detailed in Achieve’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Achieve undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Achieve Contact
Investor Relations
Nicole Jones
ir@achievelifesciences.com
425-686-1510

References
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.
²World Health Organization. WHO Report on the Global Tobacco Epidemic, 2025. Geneva: World Health Organization; 2025.
³U.S. Department of Health and Human Services. The Health Consequences of Smoking, 50 Years of Progress. A Report of the Surgeon General. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
⁴Eunice Park-Lee, Lauren M Dutra, Hannah Cowan, et al. Tobacco Product Use Among Middle and High School Students in the United States: National Youth Tobacco Survey, 2025, Nicotine & Tobacco Research, 2026; ntag116, doi.org/10.1093/ntr/ntag116.

Proposed Acquisition Would Mark ECGI’s Entry into the $5.3 Trillion U.S. Healthcare Industry with an Experienced Operating Team Across Medicare Advantage, Healthcare Services, Insurance Administration and AI-Enabled Health Technology

ORANGE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — via IBN — ECGI Holdings, Inc. (OTC: ECGI) (“ECGI” or the “Company”) today announced that it has entered into a non-binding letter of intent to acquire Avanta Group, Inc. and its subsidiaries (collectively, “Avanta”). The proposed transaction represents a pivotal step in ECGI’s strategy to build a diversified healthcare platform spanning a developing Medicare Advantage health plan, healthcare management services, health technology, consumer health and supporting real estate infrastructure.

The proposed acquisition remains subject to due diligence, negotiation and execution of definitive agreements, required corporate and regulatory approvals, and customary closing conditions. Avanta Health Plan, Inc. is in development and will require applicable approvals and licenses, including from the California Department of Managed Health Care and the Centers for Medicare & Medicaid Services, before it may operate or enroll members.

Proposed Transaction Structure

Under the letter of intent, ECGI would acquire Avanta Group, Inc. and its subsidiaries for up to 15,600,000 shares of newly designated Series V Preferred Stock. Twenty percent of the consideration would vest upon execution of a definitive agreement and be issued only at closing. The remaining 80% would vest in four equal tranches upon achievement of recurring revenue milestones of $100 million, $200 million, $300 million and $400 million, with any unvested shares contemplated to vest automatically on the fifth anniversary of closing. Each vested and issued Series V share would be convertible into 1,000 shares of ECGI common stock, subject to the definitive agreements, the Certificate of Designation and applicable law. ECGI would designate the new Series V Preferred Stock, with its additional terms to be disclosed in the definitive transaction documents and applicable public filings.

The parties are proceeding with due diligence and negotiation of definitive transaction documents. There can be no assurance that a definitive agreement will be reached, that regulatory or other approvals will be obtained, or that the proposed acquisition will be completed on the contemplated terms or at all.

“This is a pivotal moment for ECGI,” said Jamie Steigerwald, President of ECGI Holdings. “The Avanta platform is designed to connect the core functions that increasingly shape healthcare performance: insurance, administration, technology, member engagement and the infrastructure required to support delivery. We believe that combination can give ECGI a scalable foundation for growth while keeping the member experience and responsible use of data at the center of the strategy.”

Steigerwald continued, “Healthcare is one of the largest and most consequential sectors of the U.S. economy. Our objective is not simply to participate in that market, but to build an integrated platform capable of using automation and artificial intelligence to improve navigation, identify opportunities for earlier intervention, streamline administrative workflows and support more informed decision-making. We intend to pursue that opportunity with disciplined execution, strong governance and appropriate privacy, cybersecurity, clinical and regulatory controls.”

“We are excited to embark on this venture together with ECGI at such an important stage in Avanta’s development,” said Chi Luong, Chair of the Board of Avanta Group, Inc. “ECGI shares our vision of building a connected healthcare platform that combines insurance, operating expertise and technology to improve how members access and experience care. We believe this transaction can provide the strategic foundation and public-market platform needed to advance that vision, expand our capabilities and create meaningful long-term value for patients, partners and shareholders.”

The $5.3 Trillion United States Healthcare Market

The proposed transaction would position ECGI within a large healthcare market supported by long-term demographic demand. According to the Centers for Medicare & Medicaid Services (CMS), U.S. national health expenditures grew 7.2% to $5.3 trillion in 2024, representing 18.0% of gross domestic product. Medicare spending accounted for approximately $1.12 trillion of that total, while private health insurance spending reached approximately $1.64 trillion. CMS projects that Medicare spending will grow by an average of 7.7% annually from 2025 through 2034, faster than other major sources of healthcare funding.

The Medicare Advantage Market

Medicare Advantage is a substantial part of the broader healthcare market. In February 2026, approximately 35.5 million people were enrolled in Medicare Advantage plans, representing 55% of beneficiaries eligible to enroll. CMS also projected that its final 2026 payment policies would increase payments to Medicare Advantage plans by 5.06%, or more than $25 billion, compared with 2025.

ECGI believes the scale of Medicare Advantage, combined with advances in AI-enabled health technology, presents opportunities to improve member engagement, care navigation, risk identification and administrative efficiency. These remain strategic objectives. Their development and deployment will depend on regulatory requirements, data availability, validation and operational readiness.

The Proposed Avanta Platform

• Avanta Health Plan, Inc.: a developing Medicare Advantage, Commercial, and Individual health-plan insurance entity, subject to all required licenses and approvals.
• Avanta MSO, LLC: a management-services organization intended to support healthcare administration and operations within Avanta’s medical network, directly implementing Avanta Tech and Avanta Health Plan’s innovations at the clinical level.
• Avanta Tech, Inc.: a health-technology business expected to support data, automation and AI-enabled capabilities.
• Avanta Mart, LLC: a consumer-health and wellness channel intended to deepen member and community engagement.
• Avanta Properties City Parkway, LLC: a real-estate entity intended to support healthcare-related infrastructure.

If completed, ECGI expects the transaction to create a unified platform through which technology and data can support multiple operating functions. Potential applications include member-service automation, care-gap identification, provider and network analytics, claims and workflow support, fraud-waste-and-abuse detection, and personalized health navigation. No assurance can be given that any specific capability will be developed, approved, deployed or produce the anticipated results.

About ECGI Holdings

ECGI Holdings, Inc. (OTC: ECGI) is a publicly traded holding company pursuing opportunities to build and scale operating businesses in large, evolving markets.

The Company’s core AI team includes Mr. Lev, who has more than a decade of experience in machine learning, quantitative financial modeling and decentralized systems. Most recently, he led generative-AI platform integration and machine-learning infrastructure at Elation, where he built production-scale large-language-model and telemetry systems connecting enterprise data with operational decision-making. Earlier, he co-founded Skryty, an AI firm that engineered a GPU-accelerated trading engine capable of real-time pattern recognition across NASDAQ market feeds. His prior work at Goldman Sachs and Bloomberg adds deep experience in signal generation, large-scale data engineering and applied financial intelligence. Additional information is available through the Company’s public disclosures.

About Avanta Group

Avanta Group, Inc. is developing a diversified healthcare platform across Medicare Advantage, healthcare management services, health technology, consumer health and supporting real estate. Avanta Health Plan’s contemplated operations remain subject to required licenses and regulatory approvals. Avanta was founded by a team of healthcare operations executives who have a successful track record of building other Medicare Advantage plans and medical clinics. The team understands the needs of diverse ethnic groups related to their health benefits and well-being.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, among other things, statements regarding the proposed acquisition of Avanta; the negotiation and execution of definitive agreements; the creation and terms of Series V Preferred Stock; the issuance, vesting and conversion of transaction consideration; regulatory and corporate approvals; Avanta Health Plan’s licensing, launch and enrollment; the development and deployment of AI-enabled technologies; anticipated synergies, market opportunities, operating performance and growth. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Such risks include the parties’ ability to complete due diligence and agree on definitive terms; financing and capital requirements; dilution; regulatory, licensing and compliance requirements; cybersecurity and data-privacy risks; technology-development and validation risks; competition; reimbursement and policy changes; and other risks described in ECGI’s filings and public disclosures. Readers should not place undue reliance on forward-looking statements. ECGI undertakes no obligation to update such statements except as required by law.

Investor Relations, Media Relations and Corporate Communications
Investor Relations
jamie@ecgiholdings.com

Media Relations
media@nightfoodholdings.com

Corporate Communications
Editor@InvestorBrandNetwork.com
IBN | Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000

Market Data Sources

Centers for Medicare & Medicaid Services, National Health Expenditure Fact Sheet: CMS NHE Fact Sheet

Medicare Payment Advisory Commission, July 2026 Data Book: Health Care Spending and the Medicare Program

Third Wave of Ownership-Group Approvals; Commercial Rollout Expected Across 41 Additional Supermarket Locations

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, announces that, further to its news releases dated March 30, 2026 and July 30, 2026, it has been approved to expand its commercial rollout into two additional ownership groups totaling 41 stores of a top-tier U.S. supermarket brand, ranked among North America’s top-30 food retailers by annual sales.¹

“The first two ownership groups validated the model. This third planned expansion is traction: a vote of confidence from two more ownership groups and 41 additional stores. It shows the potential scale of the U.S. opportunity. And it is only the start,” said Jonathan Or, CEO of Beyond Oil. “We built our U.S. commercial platform to win large multi-location customers and serve them directly. Food retail is now a major growth vertical for Beyond Oil, and we are positioned to keep converting across this network, with the potential to scale across hundreds of supermarkets in multiple states.”

This is the Company’s third expansion with ownership groups of the same supermarket brand. The first ownership group, announced March 30, 2026, followed a successful pilot with an initial commercial rollout across 13 locations. The second ownership group, announced July 30, 2026, added the rollout commitment for 14 high-volume supermarket locations, four of which were already operational at announcement. The two newly approved ownership groups are expected to add 41 high-volume locations.

Following the successful rollouts with the first and second ownership groups, Beyond Oil worked to fine-tune the program, ensure strong operator compliance and build an effective model for broader rollout. Those rollouts delivered strong operator satisfaction and measurable performance improvements, aligned with the broader supermarket brand’s priorities around food quality, worker safety and more sustainable kitchen operations. That operating model is now converting across the network.

The two additional ownership groups operate a combined 41 high-volume supermarket locations. Deployment across these locations is planned to proceed as the Company and the operators complete onboarding, training, initial location implementation, validate results, and then broader installation.

This milestone marks Beyond Oil’s continued scaling into the high-potential food retail vertical, where prepared-food programs represent a fast-growing segment characterized by very high frying volumes and strong recurring product usage. The Company believes this vertical represents a substantial expansion opportunity alongside its existing focus on quick-service restaurant chains and other foodservice operators.

About Beyond Oil Ltd.

We all love fried food. Let’s make it better. Not by changing what people love. By improving the system behind it. Beyond Oil Ltd. (TSX: BOIL, OTCQB: BEOLF) is a food-tech innovation company on a mission to help foodservice operators improve fried food across every dimension that matters: quality, health, consistency, safety, sustainability and profitability. We achieve these outcomes by improving the system behind every kitchen, the frying performance and oil management that determine what lands on the plate. The Company’s patented technology, cleared by the FDA and Health Canada, integrates into existing kitchen workflows to improve frying performance and oil management, helping operators deliver more consistent food, strengthen operational control and reduce oil waste. Beyond Oil’s solution serves restaurant chains, supermarkets, hotels, catering, institutions and industrial frying operations worldwide, turning frying into a measurable, repeatable and scalable brand standard. The result is a better frying standard, helping every fryer, every shift and every plate live up to the food people love. For more information, please visit: www.beyondoil.co.

Forward-Looking Statements and Information

This news release contains “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of other relevant securities legislation, including applicable securities laws in Canada, which reflect Beyond Oil Ltd.’s current views with respect to, among other things, its operations and financial performance (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions and which are in turn based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. The estimates, beliefs and assumptions of Beyond Oil Ltd. are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and as such, are subject to change. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions. Although Beyond Oil Ltd., believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in the USA and Canada, certain factors, not presently known to Beyond Oil Ltd., or that Beyond Oil Ltd., currently believes are not material, could cause actual results to differ materially from those contemplated or implied by forward-looking statements. Readers are urged to consider these risks, as well as other uncertainties, factors and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to us as of the date of this news release. Except as required by law, Beyond Oil Ltd., undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Adi Olesker, VP of Investor Relations
Phone: +972-50-694-2517
adio@beyondoil.co

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
BOIL@arxhq.com

¹ Ranking source: Progressive Grocer, Julia Tabisz, “The PG 100: The 2026 Ranking of Top Food Retailers,” May 11, 2026. https://progressivegrocer.com/pg-100-2026-ranking-top-food-retailers

Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown

Findings validate that physiological lipoprotein levels are sufficient for cellular entry without requiring artificial nanoparticles, supporting systemic administration in the Company’s Phase 2/3 clinical program

Grand Cayman, Cayman Islands, Sept. 28, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced positive new findings from an ongoing translational study evaluating the cellular uptake and gene-silencing mechanism of its lead candidate, SIL204. The study, part of the Company’s translational research program supporting its Phase 2/3 clinical development, demonstrates that SIL204 effectively harnesses naturally occurring circulating lipoproteins to achieve cellular internalization and drive potent, dose-dependent knockdown of mutant KRAS oncogene expression in cancer cells.

Extending oligonucleotide delivery beyond the liver represents a major frontier in RNAi therapeutics.¹ The newly reported findings demonstrate that SIL204 is designed to utilize native lipid transport pathways to achieve intracellular delivery in tumor cells. In the study, conducted in a carrier-free, non-transfection assay without synthetic transfection reagents, human KRAS-driven cancer cells treated with SIL204 exhibited robust, dose-dependent gene silencing in the presence of standard physiological serum lipids. In contrast, depletion of serum lipids resulted in a statistically significant reduction in gene-knockdown efficiency (P < 0.001), confirming that circulating lipoproteins play a direct, functional role in mediating SIL204 cellular uptake and oncogenic silencing.²

Importantly, the addition of exogenous human low-density lipoprotein (LDL) did not alter gene-silencing potency compared to complete serum alone. This observation indicates that endogenous levels of circulating lipoproteins present under normal physiological conditions are already sufficient to support efficient cellular uptake and target knockdown, eliminating the need for external lipid supplementation or artificial carrier vehicles.

“These findings represent an essential mechanistic milestone in our translational characterization of SIL204,” said Dr. Mitchell Shirvan, Chief Scientific and Development Officer of Silexion Therapeutics. “One of the central design objectives of SIL204 was to engineer an oligonucleotide construct capable of entering target cancer cells efficiently while maintaining biological integrity. By demonstrating that SIL204 engages native lipoprotein pathways for cellular entry without requiring synthetic transfection reagents, we have demonstrated a fundamental biological mechanism that underpins its intracellular delivery. These results establish that standard physiological lipid levels are sufficient to enable potent target silencing, providing crucial mechanistic support as we advance our ongoing pharmacokinetic and biodistribution evaluations. Because the LDL receptor has been shown in vivo to be upregulated in cancer cells compared to healthy cells³, this represents an endogenous targeted delivery mechanism that is envisioned to improve the side effect profile in a clinically meaningful way.”

“Demonstrating this natural uptake mechanism reinforces our broader clinical development strategy and our Integrated Treatment Regimen for SIL204,” said Ilan Hadar, Chairman and Chief Executive Officer of Silexion Therapeutics. “While our Phase 2/3 clinical program in locally advanced pancreatic cancer targets the primary tumor, our vision has always encompassed systemic administration to address micro-metastases and distant disease spread. Confirming that SIL204 can leverage the body’s own lipid transport network for cellular entry provides a strong mechanistic foundation for systemic subcutaneous delivery. As we continue active site initiation and patient screening in our clinical program, these translational insights further validate the unique therapeutic potential of our next-generation RNAi platform.”

The findings emerge as Silexion continues translational characterization of SIL204 alongside clinical trial site initiation at Tel Aviv Sourasky Medical Center and regulatory clearances in Germany. Additional preclinical evaluations, including in vivo pharmacokinetic (PK), cellular uptake kinetics, and tissue biodistribution studies, are currently underway to further characterize the correlation between lipoprotein association, LDLR pathway engagement, systemic exposure, and anti-tumor activity in vivo.

About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com

Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the potential therapeutic benefits and future clinical development of SIL204, the Company’s ongoing and planned preclinical and clinical studies, including pharmacokinetic and biodistribution studies, and the potential future use of SIL204 for systemic administration, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, or “potential”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the inherent uncertainties associated with translational and preclinical research and drug development, including the risk that preliminary in vitro findings regarding cellular uptake, lipoprotein association, and gene silencing may not translate to in vivo pharmacokinetic models or clinical outcomes; (ii) Silexion’s ability to successfully complete additional preclinical and pharmacokinetic studies and initiate and conduct clinical trials, including the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer; (iii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iv) the impact of the regulatory environment and compliance complexities, including site-level approvals, conditions, and clearances required prior to study commencement at clinical sites in Israel, Germany, and other jurisdictions; (v) expectations regarding future partnerships or other relationships with third parties; (vi) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vii) Silexion’s ability to maintain its Nasdaq listing; and (viii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
info@silexion.com

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

____________________
¹ Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery 19, 673-694 (2020). DOI: https://doi.org/10.1038/s41573-020-0075-7
² Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnology 25, 1149-1157 (2007). DOI: https://doi.org/10.1038/nbt1339
³ Guillaumond F, Bidaut G, Ouaissi M, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences (PNAS) 112 (8), 2473-2478 (2015). DOI: https://doi.org/10.1073/pnas.1421601112